Filter
Top Products
Page 23 of 24
English
Leica Biosystems Leica HER2 FISH System - 30 Test Instructions for Use TA9217 EN-CE-Rev_D 08/04/2013
English
References
1. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor
related protein. Nature 1986;319:226–30.
2. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, et al. The normal erbB-
2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of
ligand. New Biologist 1990; 2: 992–1003.
3. Wolff A.C., Hammond E.H., Schwartz J.N., et al. American Society of Clinical Oncology/College of
American Pathologists Guideline recommendations for human epidermal growth factor receptor 2
testing in breast cancer. Journal of Clinical Oncology 25, 1-28, 2007.Slamon DJ, Clark GM,
4. Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplication of the
HER-2/neu oncogene. Science 1987;235:177-182.
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in
breast cancer. Journal of Clinical Oncology 1992;10:7:1049-1056.
6. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk
factor in patients with involved and uninvolved lymph nodes. British Journal of Cancer 1991;63:434-
438.
7. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplication predicts poor survival in node-
positive breast cancer. Cancer Research 1990;50:4332-4337.
8. Tandon AK, Clark GM, Chamness AU, et al. HER-2/neu oncogene protein and prognosis in breast
cancer. Journal of Clinical Oncology 1989; 7:1120-1128.
9. Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, et al. Humanization of an
anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Science
USA 1992; 89: 4285–9.
10. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal
antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor
necrosis factor. Molecular & Cell Biology 1989; 9: 1165–72.
11. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human
tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunology and Immunotherapy
1993; 37: 255–63.
12. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2
antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/
neu overexpressing human breast cancer xenografts. Cancer Research 1998; 58: 2825–31.
13. Ellis I.O., Bartlett J., Dowsett M., Humphreys S., Jasani B., Miller K., Pinder S.E., Rhodes A. and
Walker R. Best practise No. 176: Updated recommendations for Her-2 testing in the UK. Journal of
Clinical Pathology 57; 233-237, 2004.
14. Walker R.A, Bartlett, J., Dowsett, M., Ellis, I., Hanby, A., Jasani, Miller, K., Pinder, S. HER2 Testing
in the UK – further update to recommendations. Journal of Clinical Pathology 2007.054866
15. Press MF, Zhou JY, Ma Y, et al. Evaluation of HER-2/neu gene amplication by uorescence in
situ hybridization in invasive breast carcinoma. In: FISH: Clinical Applications in Cancer and Genetics
February 8-11, 1994; Lake Tahoe, CA.
16. Pauletti G, Singh R, Press MF, et al. HER-2/neu gene amplication detected by uorescence in situ
hybridization: A comparative study with other techniques. Abstract 3247, Proceedings of the American
Association for Cancer Research 1994 35:545.
17.Szöllösi J, Balázs M, Feuerstein BG, et al. Phenotype genotype relationship in erbB-2 amplication.
International Society for Analytical Cytology 1994 Abstracts. 92. Abstract 536D.
18. Kallioniemi O, Kallioniemi A, Kurisu W, et al. ERBB2 amplication in breast cancer analyzed by
uorescence in situ hybridization. Proceedings of the National Academy of Sciences 1992;89:5321-
5325.
19. The National Committee for Clinical Laboratory Standards (NCCLS). Quality assurance for
immunocytochemistry; Approved guideline. NCCLS document MM4-A (1-56238-396-5) NCCLS,
940 West Valley Road, Suite 1400, Wayne, Pennsylvania 1999; 19087–1898: USA
20. Elias JM, Gown AM, Nakamura RM, Wilbur DC, Herman GE, Jaffe ES, et al. Special Report:
Quality control in immunohistochemistry. American Journal of Clinical Pathology 1989 ;92: 836–43.
21. Nadji, M. and Morales, A. R. Immunoperoxidase, part I: the techniques and its pitfalls. Laboratory
Medicine 1983; 14: 767.
22. Jackson P. 2007. Quality Assurance in Immunohistochemistry. In: Immunohistochemistry, 2007 (ed.
Renshaw S), PP 205–237. Scion Publishing Ltd.
23. Bartlet JMS, Ibrahim M, et al External Quality Assurance of HER2 FISH Testing: Results of a UK
NEQAS Pilot Scheme. Journal of Clinical Pathology. 2006.